{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T08:22:13Z","timestamp":1791793333892,"version":"4.3.4"},"reference-count":39,"publisher":"Pharmaceutical Society of Japan","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,10,10]]},"DOI":"10.1248\/bpb.b25-00361","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T22:09:30Z","timestamp":1760047770000},"page":"1493-1502","source":"Crossref","is-referenced-by-count":2,"title":["Association of Plasma Creatinine with Systemic Exposure to S-1 and Oxaliplatin in Two Types of Chronic Kidney Disease Animal Models"],"prefix":"10.1248","volume":"48","author":[{"given":"Takumi","family":"Tanaka","sequence":"first","affiliation":[{"name":"Laboratory of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto 607\u20138414, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aika","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto 607\u20138414, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kobuchi","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto 607\u20138414, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukako","family":"Ito","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto 607\u20138414, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Sakaeda","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto 607\u20138414, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Ishii T, Fujimaru T, Nakano E, Takahashi O, Nakayama M, Yamauchi T, Komatsu Y. Association between chronic kidney disease and mortality in stage IV cancer. Int. J. Clin. Oncol.<\/i>, 25<\/b>, 1587\u20131595 (2020).","DOI":"10.1007\/s10147-020-01715-9"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Velenosi TJ, Urquhart BL. Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis. Expert Opin. Drug Metab. Toxicol.<\/i>, 10<\/b>, 1131\u20131143 (2014).","DOI":"10.1517\/17425255.2014.931371"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Tangri N, Rastogi A, Nekeman-Nan C, Hong LS, Ozaki A, Franz\u00e9n S, Sofue T. Dapagliflozin utilization in chronic kidney disease and its real-world effectiveness among patients with lower levels of albuminuria in the U.S.A. and Japan. Adv. Ther.<\/i>, 41<\/b>, 1151\u20131167 (2024).","DOI":"10.1007\/s12325-023-02773-x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Sunami E, Kusumoto T, Ota M, et al<\/i>. S-1 and oxaliplatin versus tegafur-uracil and leucovorin as postoperative adjuvant chemotherapy in patients with high-risk stage III colon cancer (ACTS-CC 02): a randomized, open-label, multicenter, phase III superiority trial. Clin. Colorectal Cancer<\/i>, 19<\/b>, 22\u201331.e6 (2020).","DOI":"10.1016\/j.clcc.2019.10.002"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Booka E, Imamura CK, Takeuchi H, Hamamoto Y, Gomi D, Mizukami T, Ichiyama T, Tateishi K, Takahashi T, Kawakubo H, Soejima K, Boku N, Tanigawara Y, Kitagawa Y. Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study. Gastric Cancer<\/i>, 19<\/b>, 876\u2013886 (2016).","DOI":"10.1007\/s10120-015-0536-6"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Watanabe D, Fujii H, Matsuhashi N, Iihara H, Yamada Y, Ishihara T, Takahashi T, Yoshida K, Suzuki A. Dose adjustment of oxaliplatin based on renal function in patients with metastatic colorectal cancer. Anticancer Res.<\/i>, 40<\/b>, 2379\u20132386 (2020).","DOI":"10.21873\/anticanres.14207"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Filewod N, Lipman ML. Severe acute tubular necrosis observed subsequent to oxaliplatin administration. Clin. Kidney J.<\/i>, 7<\/b>, 68\u201370 (2014).","DOI":"10.1093\/ckj\/sft148"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Janus N, Launay-Vacher V, Byloos E, Machiels JP, Duck L, Kerger J, Wynendaele W, Canon JL, Lybaert W, Nortier J, Deray G, Wildiers H. Cancer and renal insufficiency results of the BIRMA study. Br. J. Cancer<\/i>, 103<\/b>, 1815\u20131821 (2010).","DOI":"10.1038\/sj.bjc.6605979"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Launay-Vacher V, Janus N, Deray G. Renal insufficiency and cancer treatments. ESMO Open<\/i>, 1<\/b>, e000091 (2016).","DOI":"10.1136\/esmoopen-2016-000091"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Kim K, Anderson EM, Thome T, Lu G, Salyers ZR, Cort TA, O\u2019Malley KA, Scali ST, Ryan TE. Skeletal myopathy in CKD: a comparison of adenine-induced nephropathy and 5\/6 nephrectomy models in mice. Am. J. Physiol. Renal Physiol.<\/i>, 321<\/b>, F106\u2013F119 (2021).","DOI":"10.1152\/ajprenal.00117.2021"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Takayama J, Takaoka M, Matsumura Y. Acute and chronic renal failure model in rats and mice. Nippon Yakurigaku Zasshi<\/i>, 131<\/b>, 37\u201342 (2008).","DOI":"10.1254\/fpj.131.37"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Diwan V, Brown L, Gobe GC. Adenine-induced chronic kidney disease in rats. Nephrology<\/i>, 23<\/b>, 5\u201311 (2018).","DOI":"10.1111\/nep.13180"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Rahman A, Yamazaki D, Sufiun A, Kitada K, Hitomi H, Nakano D, Nishiyama A. A novel approach to adenine-induced chronic kidney disease associated anemia in rodents. PLOS ONE<\/i>, 13<\/b>, e0192531 (2018).","DOI":"10.1371\/journal.pone.0192531"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Tokunaga A, Miyamoto H, Fumoto S, Nishida K. Effect of chronic kidney disease on hepatic clearance of drugs in rats. Biol. Pharm. Bull.<\/i>, 43<\/b>, 1324\u20131330 (2020).","DOI":"10.1248\/bpb.b20-00124"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Tanaka T, Kobuchi S, Ito Y, Sakaeda T. Pharmacokinetic evaluation of oxaliplatin combined with S-1 (SOX) chemotherapy in a rat model of colorectal cancer with acute kidney injury: predictive renal biomarkers for dose optimization. Xenobiotica<\/i>, 53<\/b>, 613\u2013620 (2023).","DOI":"10.1080\/00498254.2023.2283736"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Seetharam R, Sood A, Goel S. Oxaliplatin: pre-clinical perspectives on the mechanisms of action, response, and resistance. Ecancermedicalscience<\/i>, 3<\/b>, 153 (2009).","DOI":"10.3332\/ecancer.2009.153"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Kobuchi S, Kai M, Ito Y. Population pharmacokinetic model-based evaluation of intact oxaliplatin in rats with acute kidney injury. Cancers<\/i>, 13<\/b>, 6382 (2021).","DOI":"10.3390\/cancers13246382"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Inoue S, Ohtani H, Tsujimoto M, Hori S, Sawada Y. Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil, and oteracil potassium. Drug Metab. Pharmacokinet.<\/i>, 22<\/b>, 162\u2013168 (2007).","DOI":"10.2133\/dmpk.22.162"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Kobuchi S, Ito Y, Nakano Y, Sakaeda T. Population pharmacokinetic modeling and simulation of 5-fluorouracil incorporating a circadian rhythm in rats. Xenobiotica<\/i>, 46<\/b>, 597\u2013604 (2016).","DOI":"10.3109\/00498254.2015.1100767"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kobuchi S, Katsuyama Y, Ito Y. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of oxaliplatin for hematological toxicity in rats. Xenobiotica<\/i>, 50<\/b>, 223\u2013230 (2020).","DOI":"10.1080\/00498254.2019.1601790"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Ulusakarya A, Misra S, Haydar M, Habert H, Castagne V, Gumus Y, Delmas-Marsalet B, Machover D. Acute renal failure related to oxaliplatin-induced intravascular hemolysis. Med. Oncol.<\/i>, 27<\/b>, 1425\u20131426 (2010).","DOI":"10.1007\/s12032-009-9263-3"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Ciorcan M, Chisavu L, Mihaescu A, Gadalean F, Bob FR, Negru S, Schiller OM, Grosu ID, Marc L, Chisavu F, Dragota Pascota R, Apostol A, Ivan V, Schiller A. Chronic kidney disease in cancer patients, the analysis of a large oncology database from Eastern Europe. PLOS ONE<\/i>, 17<\/b>, e0265930 (2022).","DOI":"10.1371\/journal.pone.0265930"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Huang MC, Chen ME, Hung HC, Chen HC, Chang WT, Lee CH, Wu YY, Chiang HC, Hwang SJ. Inadequate energy and excess protein intakes may be associated with worsening renal function in chronic kidney disease. J. Ren. Nutr.<\/i>, 18<\/b>, 187\u2013194 (2008).","DOI":"10.1053\/j.jrn.2007.08.003"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Yokozawa T, Zheng PD, Oura H, Koizumi F. Animal model of adenine-induced chronic renal failure in rats. Nephron J.<\/i>, 44<\/b>, 230\u2013234 (1986).","DOI":"10.1159\/000183992"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Klinkhammer BM, Djudjaj S, Kunter U, Palsson R, Edvardsson VO, Wiech T, Thorsteinsdottir M, Hardarson S, Foresto-Neto O, Mulay SR, Moeller MJ, Jahnen-Dechent W, Floege J, Anders HJ, Boor P. Cellular and molecular mechanisms of kidney injury in 2,8-dihydroxyadenine nephropathy. J. Am. Soc. Nephrol.<\/i>, 31<\/b>, 799\u2013816 (2020).","DOI":"10.1681\/ASN.2019080827"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Nelson AW, Mackinnon B, Traynor J, Geddes CC. The relationship between serum creatinine and estimated glomerular filtration rate: implications for clinical practice. Scott. Med. J.<\/i>, 51<\/b>, 5\u20139 (2006).","DOI":"10.1258\/RSMSMJ.51.4.5"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Saito H, Miyakoshi N, Kasukawa Y, Nozaka K, Tsuchie H, Sato C, Abe K, Shoji R, Shimada Y. Analysis of bone in adenine-induced chronic kidney disease model rats. Osteoporos. Sarcopenia<\/i>, 7<\/b>, 121\u2013126 (2021).","DOI":"10.1016\/j.afos.2021.11.001"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Chevalier RL. The proximal tubule is the primary target of injury and progression of kidney disease: role of the glomerulotubular junction. Am. J. Physiol. Renal Physiol.<\/i>, 311<\/b>, F145\u2013F161 (2016).","DOI":"10.1152\/ajprenal.00164.2016"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Takeda F, Oda M, Terasaki M, Kubota A, Asada K, Ichimura Y, Kojima H, Saitoh H. Downregulated expression of organic anion transporting polypeptide (Oatp) 2b1 in the small intestine of rats with acute kidney injury. Drug Metab. Pharmacokinet.<\/i>, 40<\/b>, 100411 (2021).","DOI":"10.1016\/j.dmpk.2021.100411"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Bartochowski P, Gayrard N, Bornes S, Druart C, Argil\u00e9s A, Cordaillat-Simmons M, Duranton F. Gut-kidney axis investigations in animal models of chronic kidney disease. Toxins<\/i>, 14<\/b>, 626 (2022).","DOI":"10.3390\/toxins14090626"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Yoshisue K, Kanie S, Nishimura T, Chikamoto J, Nagayama S. Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats. J. Pharm. Pharmacol.<\/i>, 61<\/b>, 1643\u20131651 (2009).","DOI":"10.1211\/jpp\/61.12.0009"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Gu\u00e9vin C, Michaud J, Naud J, Leblond FA, Pichette V. Down-regulation of hepatic cytochrome P450 in chronic renal failure: role of uremic mediators. Br. J. Pharmacol.<\/i>, 137<\/b>, 1039\u20131046 (2002).","DOI":"10.1038\/sj.bjp.0704951"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) L\u00e9vi F, Metzger G, Massari C, Milano G. Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin. Pharmacokinet.<\/i>, 38<\/b>, 1\u201321 (2000).","DOI":"10.2165\/00003088-200038010-00001"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur. J. Cancer<\/i>, 39<\/b>, 112\u2013119 (2003).","DOI":"10.1016\/S0959-8049(02)00411-2"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Pinato O, Musetti C, Farrell NP, Sissi C. Platinum-based drugs and proteins: reactivity and relevance to DNA adduct formation. J. Inorg. Biochem.<\/i>, 122<\/b>, 27\u201337 (2013).","DOI":"10.1016\/j.jinorgbio.2013.01.007"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Koellensperger G, Hann S. Ultra-fast HPLC-ICP-MS analysis of oxaliplatin in patient urine. Anal. Bioanal. Chem.<\/i>, 397<\/b>, 401\u2013406 (2010).","DOI":"10.1007\/s00216-010-3504-3"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Cunha RS, Santos AF, Barreto FC, Stinghen AEM. How do uremic toxins affect the endothelium? Toxins<\/i>, 12<\/b>, 412 (2020).","DOI":"10.3390\/toxins12060412"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Hironaka S, Sadachi R, Machida N, Iwasa S, Yamada Y, Sasako M, Yoshikawa T, Boku N, Terashima M. Association of renal function with the safety and efficacy of cisplatin plus S-1 therapy and docetaxel plus cisplatin plus S-1 therapy in patients with advanced gastric cancer: an exploratory analysis of JCOG1013. Jpn. J. Clin. Oncol.<\/i>, 52<\/b>, 14\u201323 (2022).","DOI":"10.1093\/jjco\/hyab160"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Wason S, Mount D, Faulkner R. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clin. Drug Investig.<\/i>, 34<\/b>, 845\u2013855 (2014).","DOI":"10.1007\/s40261-014-0238-6"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/10\/48_b25-00361\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T03:41:22Z","timestamp":1760154082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/10\/48_b25-00361\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00361","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"article-number":"b25-00361"}}